FIELD: medicine.
SUBSTANCE: proposed group of inventions relates to medicine. Disclosed is a therapeutic agent for treating a human having cancer containing recombinant orthopoxvirus MVA-BN and an antagonist of anti-PD-1, which is an antibody. Disclosed is a method of treating a human having cancer, comprising administering to a patient a recombinant orthopoxvirus MVA-BN and said antagonist.
EFFECT: proposed group of inventions provides a synergetic effect associated with recombinant orthopoxvirus and antagonist anti-PD-1.
22 cl, 23 dwg, 24 ex
| Title |
Year |
Author |
Number |
| COMBINED THERAPY FOR TREATING CANCER USING A RECOMBINANT POXVIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST OR AGONIST OF AN IMMUNE CONTROL POINT MOLECULE |
2015 |
- Foy Susan
- Mandl Stefanie
- Rountree Ryan
- Franzusoff Alex
|
RU2724433C2 |
| THERAPY FOR TREATING CANCER BY INTRATUMORAL AND/OR INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA CODING 4-1BBL (CD137L) AND/OR CD40L |
2019 |
- Lauterbach, Henning
- Hinterberger, Maria
- Medina Echeverz, Jose
|
RU2830601C2 |
| COMBINATION THERAPY FOR CANCER TREATMENT USING RECOMBINANT MVA AND ANTIBODIES INTRODUCED INTRAVENOUSLY |
2018 |
- Hochrein, Hubertus
- Lauterbach, Henning
- Medina Echeverz, Jose
- Habjan, Matthias
|
RU2795103C2 |
| USING MVA (MODIFIED VACCINIA ANKARA) FOR TREATING PROSTATE CANCER |
2008 |
- Del'Kehr Alen
- Laus Rajner
- Mehndl Stefani
- Rauntri Rajan Blehr
- Legrand Fatema
|
RU2499606C2 |
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS |
2017 |
- Kezada, Serkhio
- Peggs, Karl
- Arse Vargas, Frederik
|
RU2759970C2 |
| COMPOSITIONS AND METHODS OF TREATING INFECTIONS AND TUMOURS |
2007 |
- Akhmed Rafi
- Amara Rama
- Friman Gordon
- Sharp Ehrlin
|
RU2540490C2 |
| COMPOSITIONS AND METHODS OF TREATING INFECTIONS AND TUMOURS |
2007 |
- Akhmed Rafi
- Amara Rama
- Friman Gordon
- Sharp Ehrlin
|
RU2478400C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2013 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanyuj
- Selbi Mark Dzh.
- Chen Bin
- Kardarelli Zhozefin M.
|
RU2599417C2 |
| HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2006 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanjuj
- Selbi Mark Dzh.
- Chehn' Bin
- Kardarelli Zhozefin M.
- Khuan Khajchun'
|
RU2494107C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2006 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanjuj
- Selbi Mark Dzh.
- Chehn' Bin
- Kardarelli Zhozefin M.
|
RU2406760C2 |
